



FOR IMMEDIATE RELEASE

XiMo and Aspira Scientific Launch Air-Stable Metathesis Pills

Delivering Nobel-Winning Catalysis Platform for Rapid Pharmaceutical R&D Screening

SAN FRANCISCO, Calif., October 13, 2015 /PRNewswire/ -- XiMo AG (Lucerne, Switzerland) and Aspira Scientific, Inc. (Milpitas, California) announced today the launch of air-stable catalyst pills (CatPac's) for metathesis chemistry. The importance of metathesis chemistry was highlighted by the Nobel Prize awarded in 2005 to the pioneers of this application. This industrially-relevant application has been utilized in the production of valuable chemical entities such as pharmaceuticals, specialty chemicals, and polymers.

The CatPac system was developed by XiMo, an emerging metathesis technology company and utilizes proprietary molybdenum (Mo) and tungsten (W) catalysts. "Our catalysts represent exceptional value to the chemical industry, especially in pharmaceutical development, given the low cost of Mo compared to ruthenium (Ru) (100-fold less expensive), and its high body tolerance (non-toxic as opposed to Ru)," said Douglas C. Günthardt, Chairman of XiMo. "We have made these highly active catalysts more convenient to use for rapid screening by formulating them in an air-stable pill format that we call the CatPac," added Dr. Georg Fráter, COO of XiMo. "Our catalysts are also available in native form on commercial scale."

"As a provider of innovative chemistry solutions, we are continuously launching novel tools to enable discovery and development," commented Dr. John Chan, CEO of Aspira Scientific. "We are very excited to deliver a broad Nobel-winning metathesis platform in a user- and IP-friendly manner which has been lacking in industry for some time." This latest addition complements well Aspira Scientific's broad portfolio of cutting-edge tools for drug and material development. Detailed product information for Mo-CatPac catalysts are available at: www.aspirasci.com/metathesis.

About XiMo AG

XiMo is a Swiss-based company focused on the development and application of proprietary metathesis catalysts for use in the specialty chemical, agro chemical, renewables, pharmaceutical, flavors and fragrances, polymers and advanced materials sectors. The company's molybdenum and tungsten catalysts are based on the breakthrough scientific research of founders Amir Hoveyda at Boston College and Richard Schrock at MIT, co-winner of the 2005 Nobel Prize in Chemistry. XiMo partners with selected leading companies on a time-limited exclusive basis, providing access to its intellectual property and technical expertise, to solve important industrial chemistry problems and to enable development of novel molecules and materials. Our complexes deliver both high activity and selectivity in metathesis transformations, enabling efficient Z-selective cross-metathesis, as well as enantioselective reactions. Details are available on our website: www.ximo-inc.com.

About Aspira Scientific, Inc.

Aspira Scientific is a science-centric enterprise dedicated to empowering scientists reach their aspirations in chemical R&D. We achieve this goal through reducing the cost of basic and applied research by offering research products with superior value in terms of price and quality. By leveraging a truly global innovation ecosystem, we also make available a broader set of next-generation enabling tools for chemical synthesis. For organizations with developmental programs, we provide custom production services via “Collaborate Locally. Commercialize Globally.™” model to afford exceptional value in terms of innovation, quality and IP assurance, and cost-efficiency. For more information on realizing your scientific aspirations now and tomorrow, please visit www.aspirasci.com.

MEDIA CONTACT

John Chan, Ph.D.

CEO, Aspira Scientific

john.chan@aspirasci.com

Tel: 650-224-4037

###